Equities

HUTCHMED (China) Ltd

HCM:LSE

HUTCHMED (China) Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)310.00
  • Today's Change0.00 / 0.00%
  • Shares traded17.44k
  • 1 Year change30.53%
  • Beta--
Data delayed at least 20 minutes, as of May 03 2024 16:35 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year HUTCHMED (China) Ltd grew revenues 96.52% from 426.41m to 838.00m while net income improved from a loss of 360.84m to a gain of 100.78m.
Gross margin54.12%
Net profit margin12.06%
Operating margin2.19%
Return on assets8.76%
Return on equity15.03%
Return on investment13.36%
More ▼

Cash flow in USDView more

In 2023, cash reserves at HUTCHMED (China) Ltd fell by 29.69m. However, the company earned 219.26m from its operations for a Cash Flow Margin of 26.16%. In addition the company generated 48.66m cash from financing while 291.14m was spent on investing.
Cash flow per share0.9933
Price/Cash flow per share31.32
Book value per share6.55
Tangible book value per share6.55
More ▼

Balance sheet in USDView more

HUTCHMED (China) Ltd has a Debt to Total Capital ratio of 10.38%, a higher figure than the previous year's 3.82%.
Current ratio2.72
Quick ratio2.60
Total debt/total equity0.1179
Total debt/total capital0.1038
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.